David B. Hall

7.5k citations

58 papers · 5.0k · 3 hit papers · h-index 31

Impact in

Virology top 0.5%
- HIV Research and Treatment
Infectious Diseases top 0.5%
- HIV/AIDS drug development and treatment
- HIV/AIDS Research and Interventions

Papers in

Infectious Diseases 26
- HIV/AIDS drug development and treatment 23
- HIV/AIDS Research and Interventions 13
Virology 22
- HIV Research and Treatment 22

Co-authors: John M. Torkelson (9 shared papers)Lynna M. Lesko (2 shared papers)Patrick T. Underhill (1 shared paper)Ulrich Meier (2 shared papers)Jes Olesen (1 shared paper)Ingo W. Husstedt (1 shared paper)Peter J. Goadsby (1 shared paper)Hans‐Christoph Diener (1 shared paper)
Journals: AIDS (7 papers)AIAA Journal (3 papers)Macromolecules (3 papers)American Journal of Epidemiology (3 papers)JAIDS Journal of Acquired Immune Deficiency Syndromes (2 papers)
Partner nations: United States Netherlands Canada

In The Last Decade

David B. Hall

56 papers receiving 4.8k citations

David B. Hall's Hit Papers

align trajectories log scale

Trial of Spesolimab for Generalized Pustular Psoriasis 2021 · 194 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2021 New England Journal of Medicine
2004 New England Journal of Medicine
1998 JAMA

Peers

Countries citing papers authored by David B. Hall

Since Specialization

Citations

This map shows the geographic impact of David B. Hall's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David B. Hall with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David B. Hall more than expected).

Fields of papers citing papers by David B. Hall

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David B. Hall. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David B. Hall. The network helps show where David B. Hall may publish in the future.

Co-authors

The 25 scholars most cited alongside David B. Hall, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with David B. Hall Line = papers co-authored together David B. Hall links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 58 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Calcitonin Gene–Related Peptide Receptor Antagonist BIBN 4096 BS for the Acute Treatment of Migraine New England Journal of Medicine ·Jes Olesen, Hans‐Christoph Diener, Ingo W. Husstedt, Peter J. Goadsby, David B. Hall, Ulrich Meier, Stephane Pollentier, Lynna M. Lesko Hit paper breakdown →	2004	945
2	A Randomized, Double-blind Trial Comparing Combinations of Nevirapine, Didanosine, and Zidovudine for HIV-Infected Patients JAMA ·Julio Montaner, Peter Reiß, David A. Cooper, Stefano Vella, Marianne Harris, Brian Conway, Mark A. Wainberg, Danielle M. Smith, Patrick Robinson, David B. Hall, Maureen Myers, J. M. A. Lange, For The Opposites Attract Study Group Hit paper breakdown →	1998	611
3	Spin coating of thin and ultrathin polymer films Polymer Engineering and Science ·David B. Hall, Patrick T. Underhill, John M. Torkelson	1998	399
4	Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study Annals of the Rheumatic Diseases ·Dominique Baeten, Mikkel Østergaard, James Cheng‐Chung Wei, Joachim Sieper, Pentti A. Järvinen, Lai‐Shan Tam, Carlo Salvarani, Tae‐Hwan Kim, Alan M. Solinger, Yakov Datsenko, Chandrasena Pamulapati, Sudha Visvanathan, David B. Hall, Stella Aslanyan, Paul Scholl, Steven J. Padula	2018	279
5	A Multicenter Randomized Controlled Trial of Nevirapine Versus a Combination of Zidovudine and Lamivudine to Reduce Intrapartum and Early Postpartum Mother‐to‐Child Transmission of Human Immunodeficiency Virus Type 1 The Journal of Infectious Diseases ·Dhayendre Moodley, Jagidesa Moodley, Hoosen Coovadia, Glenda Gray, James McIntyre, Justus Hofmyer, Cheryl Nikodem, David B. Hall, Maria Gigliotti, Patrick Robinson, Lynette Boshoff, John L. Sullivan, (unknown)	2003	237
6	Nevirapine and Efavirenz Elicit Different Changes in Lipid Profiles in Antiretroviral- Therapy-Naive Patients Infected with HIV-1 PLoS Medicine ·Frank van Leth, Prahpan Phanuphak, Erik S.G. Stroes, Brian Gazzard, Pedro Cahn, François Raffi, Robin Wood, Mark Bloch, Christine Katlama, John J.P. Kastelein, Mauro Schechter, Robert L. Murphy, Andrzej Horban, David B. Hall, Joep M. A. Lange, Peter Reiss	2004	208
7	Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy AIDS ·Janet Raboud, Joan Montaner, Brian Conway, Sandra Rae, Peter Reiß, Stefano Vella, David A. Cooper, Joep M. A. Lange, Marianne Harris, Mark A. Wainberg, Patrick Robinson, Maureen Myers, David B. Hall	1998	196
8	Trial of Spesolimab for Generalized Pustular Psoriasis New England Journal of Medicine ·H. Bachelez, Siew Eng Choon, Slaheddine Marrakchi, A. David Burden, Tsen‐Fang Tsai, Akimichi Morita, Alexander A. Navarini, Min Zheng, Jinhua Xu, H. Turki, Milan J. Anadkat, Sushmita Rajeswari, Hairui Hua, Sebastian D. Vulcu, David B. Hall, Kay Tetzlaff, Christian Thoma, Mark Lebwohl Hit paper breakdown →	2021	194
9	High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals AIDS ·Agnes I. Veldkamp, Gerrit Jan Weverling, Joep M. A. Lange, Julio Montaner, Peter Reiss, David A. Cooper, Stefano Vella, David B. Hall, Jos H. Beijnen, Richard M. W. Hoetelmans	2001	178
10	Aptiganel Hydrochloride in Acute Ischemic Stroke JAMA ·Gregory W. Albers, Larry B. Goldstein, David B. Hall, Lynna M. Lesko, for the RED-CABG Steering Committee and Investigators	2001	127
11	Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent AIDS ·Jing Yuan, Sheng Guo, David B. Hall, Anna M Cammett, Supriya Jayadev, M. Distel, Stephen P. Storfer, Zimei Huang, Piroon Mootsikapun, Kiat Ruxrungtham, Daniel Podzamczer, David W. Haas	2011	110
12	Genotypic Changes in Human Immunodeficiency Virus Type 1 Protease Associated with Reduced Susceptibility and Virologic Response to the Protease Inhibitor Tipranavir Journal of Virology ·John D. Baxter, Jonathan Schapiro, Charles A. Boucher, Veronika Kohlbrenner, David B. Hall, Joseph Schérer, Douglas L. Mayers	2006	108
13	Translation-Rotation Paradox for Diffusion in Glass-Forming Polymers: The Role of the Temperature Dependence of the Relaxation Time Distribution Physical Review Letters ·David B. Hall, Ali Dhinojwala, John M. Torkelson	1997	107
14	Antiviral Effect and Pharmacokinetic Interaction between Nevirapine and Indinavir in Persons Infected with Human Immunodeficiency Virus Type 1 The Journal of Infectious Diseases ·Robert L. Murphy, Jean‐Pierre Sommadossi, Michael Lamson, David B. Hall, Maureen Myers, Alex Dusek	1999	99
15	Ultrathin Polymer Films near the Glass Transition: Effect on the Distribution of α-Relaxation Times As Measured by Second Harmonic Generation Macromolecules ·David B. Hall, Jacob C. Hooker, John M. Torkelson	1997	96
16	Immune restoration does not invariably occur following long-term HIV-1 suppression during antiretroviral therapy AIDS ·Nadine G. Pakker, Eugene D.M.B. Kroon, Marijke Roos, Sigrid A. Otto, David B. Hall, Ferdinand W.N.M. Wit, Dörte Hamann, Marina E. van der Ende, Frans A.P. Claessen, Robert H. Kauffmann, Peter P. Koopmans, Frank P. Kroon, Chris H.H. ten Napel, Herman G. Sprenger, Hugo M. Weigel, Julio Montaner, Joep M. A. Lange, Peter Reiss, P T Schellekens, Frank Miedema	1999	87
17	Recommendations for safety planning, data collection, evaluation and reporting during drug, biologic and vaccine development: a report of the safety planning, evaluation, and reporting team Clinical Trials ·Brenda Crowe, H. Amy Xia, Jesse A. Berlin, Douglas J. Watson, Hongliang Shi, Stephen L Lin, Juergen Kuebler, Robert C Schriver, Nancy C. Santanello, G. D. Rochester, Jane Porter, Manfred Oster, Devan V. Mehrotra, Zhengqing Li, Eileen King, Ernest S. Harpur, David B. Hall	2009	78
18	Phase I/II Evaluation of Nevirapine Alone and in Combination with Zidovudine for Infection with Human Immunodeficiency Virus Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology ·Sarah H. Cheeseman, Diane V. Havlir, Margaret McLaughlin, Thomas C. Greenough, John L. Sullivan, David B. Hall, Susan E. Hattox, Stephen A. Spector, Daniel S. Stein, Maureen Myers, Douglas D. Richman	1995	76
19	Efficacy of Short-Course AZT Plus 3TC to Reduce Nevirapine Resistance in the Prevention of Mother-to-Child HIV Transmission: A Randomized Clinical Trial PLoS Medicine ·James McIntyre, Mark Hopley, Dhayendre Moodley, Marie Eklund, Glenda Gray, David B. Hall, Patrick Robinson, Douglas L. Mayers, Neil Martinson	2009	72
20	Small Molecule Probe Diffusion in Thin and Ultrathin Supported Polymer Films Macromolecules ·David B. Hall, John M. Torkelson	1998	72

About David B. Hall

David B. Hall is a scholar working on Infectious Diseases, Virology, Epidemiology, Atomic and Molecular Physics, and Optics and Physical and Theoretical Chemistry, having authored 58 papers that have together received 5.0k indexed citations. Recurring topics across this work include HIV/AIDS drug development and treatment (23 papers), HIV Research and Treatment (22 papers), HIV/AIDS Research and Interventions (13 papers), Material Dynamics and Properties (5 papers), Photochemistry and Electron Transfer Studies (5 papers), Statistical Methods in Clinical Trials (5 papers), Hepatitis C virus research (4 papers) and Hepatitis B Virus Studies (3 papers). The work is most often cited by research in Virology (1.5k citations), Infectious Diseases (2.0k citations), Psychiatry and Mental health (846 citations), Emergency Medicine (482 citations) and Pathology and Forensic Medicine (622 citations). David B. Hall has collaborated with scholars based in United States, Netherlands and Canada. Frequent co-authors include John M. Torkelson, Lynna M. Lesko, Patrick T. Underhill, Ulrich Meier, Jes Olesen, Ingo W. Husstedt, Peter J. Goadsby, Hans‐Christoph Diener, Stephane Pollentier and Patrick Robinson. Their work appears in journals such as AIDS, AIAA Journal, Macromolecules, American Journal of Epidemiology and JAIDS Journal of Acquired Immune Deficiency Syndromes.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

David B. Hall

Impact in

Papers in i

In The Last Decade

David B. Hall

David B. Hall's Hit Papers

Peers

Countries citing papers authored by David B. Hall

Fields of papers citing papers by David B. Hall

All Works

About David B. Hall

Explore authors with similar magnitude of impact

Papers in